CFO Sung Lee resigns effective May 3; board nominates two new independent directors

Vir Biotechnology, Inc.

CFO Sung Lee resigns effective May 3, 2024, to pursue other opportunity; no disagreement with company.
Board nominates Norbert Bischofberger and Ramy Farid as independent director candidates for May 29 annual meeting.
Founders Phillip Sharp and Robert Perez will not stand for reelection at the annual meeting.
Bischofberger brings 40 years biotech experience (former Gilead R&D head); Farid is CEO of Schrödinger.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sung Lee

Executive Vice President and Chief Financial Officer

VIR · Vir Biotechnology, Inc.

Effective: 2024-05-03
Filed: April 18, 2024, 7:59 PM ET

On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sung Lee resigned as Executive Vice President and Chief Financial Officer at Vir Biotechnology, Inc..

Action: resigned
Role: Executive Vice President and Chief Financial Officer

Exact text from the filing

On April 15, 2024, Sung Lee, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (the “Company”), informed the Company that he will be stepping down from his role, effective May 3, 2024, to pursue another career opportunity.

View on SEC.gov

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-100072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.